Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients

Annals of Neurology

Volumn 69, Issue 2, 2011, Pages 408-413

  Mehling, Matthias ^a,b   Hilbert, Patricia ^a   Fritz, Stefanie ^b   Durovic, Bojana ^b   Eichin, Dominik ^b   Gasser, Olivier ^b   Kuhle, Jens ^a   Klimkait, Thomas ^c   Lindberg, Raija L P ^a   Kappos, Ludwig ^a   Hess, Christoph ^b  

^a Clinical Neuroimmunology Laboratory   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FINGOLIMOD; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INFLUENZA VACCINE; SPHINGOSINE 1 PHOSPHATE;

ADAPTIVE IMMUNITY; ADULT; ANTIBODY BLOOD LEVEL; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; INFLUENZA A; INFLUENZA B; INFLUENZA VACCINATION; INJECTION SITE REACTION; MALE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; ADULT; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLUENZA VACCINES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPHINGOSINE; T-LYMPHOCYTES;

EID: 79952524342     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22352     Document Type: Article

References (20)

1. Goverman J., Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009; 9: 393-407.
2. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355-360. (Pubitemid 38133663)
3. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-1140. (Pubitemid 44394919)
4. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
5. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010; 362: 402-415.
6. Mehling M, Brinkmann V, Antel J, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008; 71: 1261-1267.
7. Vaessen LM, van Besouw NM, Mol WM, et al. FTY720 treatment of kidney transplant patients: a differential effect on B cells, naive T cells, memory T cells and NK cells. Transpl Immunol 2006; 15: 281-288.
8. Mehling M, Lindberg R, Raulf F, et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 2010; 75: 403-410.
9. Garber K., Infections cast cloud over Novartis' MS therapy. Nat Biotechnol 2008; 26: 844-845.
10. Kersh EN, Luo W, Adams DR, et al. Evaluation of the lymphocyte trafficking drug FTY720 in SHIVSF162P3-infected rhesus macaques. J Antimicrob Chemother 2009; 63: 758-762.
11. Walsh KB, Marsolais D, Welch MJ, et al. Treatment with a sphingosine analog does not alter the outcome of a persistent virus infection. Virology 2010; 397: 260-269.
12. McGill J, Legge KL., Cutting edge: contribution of lung-resident T cell proliferation to the overall magnitude of the antigen-specific CD8 T cell response in the lungs following murine influenza virus infection. J Immunol 2009; 183: 4177-4181.
13. Gasser O, Bihl FK, Wolbers M, et al. HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts. PLoS Med 2007; 4: e96.
14. Hill AB, Lee SP, Haurum JS, et al. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised. J Exp Med 1995; 181: 2221-2228.
15. Pham TH, Okada T, Matloubian M, et al. S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity 2008; 28: 122-133.
16. Cinamon G, Zachariah MA, Lam OM, et al. Follicular shuttling of marginal zone B cells facilitates antigen transport. Nat Immunol 2008; 9: 54-62. (Pubitemid 350286204)
17. Han S, Zhang X, Wang G, et al. FTY720 suppresses humoral immunity by inhibiting germinal center reaction. Blood 2004; 104: 4129-4133. (Pubitemid 39620165)
18. Pinschewer DD, Ochsenbein AF, Odermatt B, et al. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000; 164: 5761-5770. (Pubitemid 30389819)
19. Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989; 111: 223-231. (Pubitemid 19190915)
20. Mackall CL., T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells 2000; 18: 10-18.